SIMILAR PATTERNS OF AMINO ACIDS FOR 3IK3_B_0LIB2_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 31 VAL A 64 HIS A 124 LEU A 133 ALA A 143	None	0.47A	3ik3B-1h4lA: 22.9	3ik3B-1h4lA: 24.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 220 GLU A 236 MET A 240 LEU A 248 HIS A 312 LEU A 321	None	0.63A	3ik3B-1k9aA: 30.5	3ik3B-1k9aA: 30.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	GLU A 236 MET A 240 LEU A 248 VAL A 249 HIS A 312 LEU A 321	None	0.84A	3ik3B-1k9aA: 30.5	3ik3B-1k9aA: 30.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	ALA A 288 GLU A 305 MET A 309 ILE A 312 LEU A 317 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.57A	3ik3B-1opkA: 34.6	3ik3B-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	GLU A 305 MET A 309 LEU A 317 VAL A 318 HIS A 380 LEU A 389	P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) None P16 A 2 (-4.4A)	0.67A	3ik3B-1opkA: 34.6	3ik3B-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 621 GLU A 640 HIS A 790 LEU A 799 ASP A 810 PHE A 811	STI A 3 (-3.5A) STI A 3 (-3.6A) STI A 3 (-4.5A) STI A 3 (-4.4A) STI A 3 (-3.9A) STI A 3 (-3.6A)	0.84A	3ik3B-1t46A: 29.2	3ik3B-1t46A: 35.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 621 GLU A 640 VAL A 654 HIS A 790 LEU A 799 ASP A 810	STI A 3 (-3.5A) STI A 3 (-3.6A) STI A 3 (-4.3A) STI A 3 (-4.5A) STI A 3 (-4.4A) STI A 3 (-3.9A)	0.48A	3ik3B-1t46A: 29.2	3ik3B-1t46A: 35.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 367 GLU A 386 MET A 390 HIS A 459 LEU A 468	STU A 100 (-3.2A) None None None STU A 100 (-4.5A)	0.58A	3ik3B-1u59A: 31.3	3ik3B-1u59A: 38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA X 37 GLU X 54 MET X 58 LEU X 66 LEU X 137 ALA X 147	STU X 902 (-3.1A) STU X 902 ( 4.4A) None None STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.67A	3ik3B-2dq7X: 32.1	3ik3B-2dq7X: 44.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA X 37 MET X 58 LEU X 66 HIS X 128 LEU X 137 ALA X 147	STU X 902 (-3.1A) None None None STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.55A	3ik3B-2dq7X: 32.1	3ik3B-2dq7X: 44.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLU X 54 MET X 58 LEU X 66 VAL X 67 LEU X 137 ALA X 147	STU X 902 ( 4.4A) None None None STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.81A	3ik3B-2dq7X: 32.1	3ik3B-2dq7X: 44.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	MET X 58 LEU X 66 VAL X 67 HIS X 128 LEU X 137 ALA X 147	None None None None STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.74A	3ik3B-2dq7X: 32.1	3ik3B-2dq7X: 44.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 184 GLU A 201 ILE A 208 VAL A 220 HIS A 281 LEU A 290 ALA A 319	None	0.69A	3ik3B-2eu9A: 21.3	3ik3B-2eu9A: 23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 LEU A 322 VAL A 323 HIS A 384 LEU A 393 ALA A 403	H8H A 534 (-3.2A) None None None H8H A 534 (-4.5A) H8H A 534 ( 4.0A)	0.83A	3ik3B-2h8hA: 30.2	3ik3B-2h8hA: 27.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 293 LEU A 322 VAL A 323 HIS A 384 LEU A 393 ALA A 403	QUE A 1 (-3.5A) None None None QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.64A	3ik3B-2hckA: 29.8	3ik3B-2hckA: 31.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 271 MET A 292 LEU A 300 VAL A 301 HIS A 362 LEU A 371 ALA A 381	1BM A 499 (-3.6A) 1BM A 499 ( 3.8A) None None None 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A)	0.80A	3ik3B-2hk5A: 26.9	3ik3B-2hk5A: 46.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 269 GLU A 286 MET A 290 ILE A 293 LEU A 298 LEU A 370 ALA A 380	GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.39A	3ik3B-2hz0A: 33.9	3ik3B-2hz0A: 98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 269 MET A 290 ILE A 293 LEU A 298 HIS A 361 LEU A 370 ALA A 380	GIN A 600 (-3.1A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-4.3A) GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.62A	3ik3B-2hz0A: 33.9	3ik3B-2hz0A: 98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	GLU A 286 MET A 290 ILE A 293 LEU A 298 VAL A 299 LEU A 370 ALA A 380 ASP A 381	GIN A 600 (-3.6A) GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-4.6A) GIN A 600 (-4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.81A	3ik3B-2hz0A: 33.9	3ik3B-2hz0A: 98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	MET A 290 ILE A 293 LEU A 298 VAL A 299 HIS A 361 LEU A 370 ALA A 380 ASP A 381	GIN A 600 (-3.2A) GIN A 600 (-4.5A) GIN A 600 (-4.2A) GIN A 600 (-4.6A) GIN A 600 (-4.3A) GIN A 600 (-4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.75A	3ik3B-2hz0A: 33.9	3ik3B-2hz0A: 98.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	5	ALA A 452 GLU A 471 MET A 475 HIS A 544 LEU A 553	4ST A1687 (-3.3A) 4ST A1687 ( 4.6A) None None 4ST A1687 (-4.4A)	0.58A	3ik3B-2j0jA: 32.5	3ik3B-2j0jA: 19.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 31 GLU A 51 VAL A 64 LEU A 134 ALA A 144	None	0.55A	3ik3B-2jgzA: 23.0	3ik3B-2jgzA: 27.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 31 VAL A 64 HIS A 125 LEU A 134 ALA A 144	None	0.39A	3ik3B-2jgzA: 23.0	3ik3B-2jgzA: 27.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ALA A 271 GLU A 288 MET A 292 LEU A 300 VAL A 301 HIS A 362 LEU A 371 ALA A 381 ASP A 382 PHE A 383	1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.9A) None None 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.3A)	0.62A	3ik3B-2og8A: 32.0	3ik3B-2og8A: 44.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 853 ILE A 902 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-4.1A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.54A	3ik3B-2p4iA: 23.3	3ik3B-2p4iA: 38.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 515 GLU A 534 MET A 538 ILE A 541 HIS A 624 LEU A 633 ALA A 643	None	0.70A	3ik3B-2psqA: 31.8	3ik3B-2psqA: 33.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 215 LEU A 244 HIS A 319 LEU A 328 ALA A 338	ADE A 488 (-3.2A) None None ADE A 488 (-4.4A) None	0.50A	3ik3B-2qluA: 24.4	3ik3B-2qluA: 23.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 749 LEU A 780 VAL A 781 HIS A 841 LEU A 850	GW7 A 1 (-3.3A) None GW7 A 1 ( 4.7A) None GW7 A 1 (-4.2A)	0.71A	3ik3B-2r4bA: 29.0	3ik3B-2r4bA: 35.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	5	ALA A 273 LEU A 302 HIS A 365 LEU A 374 ALA A 384	None	0.44A	3ik3B-2zv7A: 25.6	3ik3B-2zv7A: 45.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 515 MET A 538 HIS A 624 LEU A 633 ALA A 643	M33 A1996 (-3.3A) None None M33 A1996 (-4.5A) None	0.55A	3ik3B-3b2tA: 25.6	3ik3B-3b2tA: 39.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 512 GLU A 531 HIS A 621 LEU A 630 ALA A 640	C4F A 1 (-3.3A) None None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.49A	3ik3B-3c4fA: 25.2	3ik3B-3c4fA: 40.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 512 MET A 535 HIS A 621 LEU A 630 ALA A 640	C4F A 1 (-3.3A) C4F A 1 ( 3.7A) None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.49A	3ik3B-3c4fA: 25.2	3ik3B-3c4fA: 40.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 220 GLU A 236 MET A 240 LEU A 248 HIS A 312 LEU A 321	None	0.63A	3ik3B-3d7uA: 31.2	3ik3B-3d7uA: 44.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLU A 236 MET A 240 LEU A 248 VAL A 249 HIS A 312 LEU A 321	None	0.84A	3ik3B-3d7uA: 31.2	3ik3B-3d7uA: 44.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ALA A 663 GLU A 682 MET A 686 VAL A 695 HIS A 756 ASP A 776 PHE A 777	IHZ A1001 (-3.3A) IHZ A1001 (-3.8A) IHZ A1001 (-3.5A) IHZ A1001 ( 4.9A) IHZ A1001 ( 4.9A) IHZ A1001 (-4.8A) IHZ A1001 (-4.7A)	0.76A	3ik3B-3dkoA: 30.9	3ik3B-3dkoA: 36.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ALA A 663 VAL A 695 ILE A 711 HIS A 756 LEU A 765 ASP A 776 PHE A 777	IHZ A1001 (-3.3A) IHZ A1001 ( 4.9A) IHZ A1001 (-3.8A) IHZ A1001 ( 4.9A) IHZ A1001 (-4.6A) IHZ A1001 (-4.8A) IHZ A1001 (-4.7A)	0.86A	3ik3B-3dkoA: 30.9	3ik3B-3dkoA: 36.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 859 GLU A 878 HIS A1020 LEU A1029 ASP A1040 PHE A1041	8ST A2001 ( 3.8A) 8ST A2001 (-3.7A) 8ST A2001 ( 4.8A) None None 8ST A2001 ( 3.7A)	0.93A	3ik3B-3hngA: 33.0	3ik3B-3hngA: 33.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	5	ALA A 665 GLU A 684 MET A 688 HIS A 758 LEU A 767	None	0.54A	3ik3B-3kulA: 25.8	3ik3B-3kulA: 34.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 46 GLU A 66 VAL A 79 LEU A 156 ALA A 166	None	0.56A	3ik3B-3mi9A: 22.7	3ik3B-3mi9A: 26.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 46 VAL A 79 HIS A 147 LEU A 156 ALA A 166	None	0.50A	3ik3B-3mi9A: 22.7	3ik3B-3mi9A: 26.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	5	ALA A 49 VAL A 82 HIS A 142 LEU A 151 ALA A 161	ADP A 314 (-3.5A) None None ADP A 314 (-4.6A) None	0.57A	3ik3B-3nizA: 22.6	3ik3B-3nizA: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 109 GLU A 130 MET A 134 HIS A 203 LEU A 212	JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) None None None	0.57A	3ik3B-3nuuA: 22.8	3ik3B-3nuuA: 26.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	ALA A 576 GLU A 596 MET A 600 HIS A 674 LEU A 683	STU A 1 (-3.3A) None None None STU A 1 (-4.3A)	0.53A	3ik3B-3ppzA: 28.4	3ik3B-3ppzA: 32.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	ALA A 576 MET A 600 VAL A 609 HIS A 674 LEU A 683	STU A 1 (-3.3A) None None None STU A 1 (-4.3A)	0.71A	3ik3B-3ppzA: 28.4	3ik3B-3ppzA: 32.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 443 MET A 464 LEU A 472 VAL A 473 HIS A 534 LEU A 543	PP2 A 1 (-3.2A) PP2 A 1 ( 4.3A) None None None PP2 A 1 (-4.6A)	0.68A	3ik3B-3sxsA: 31.3	3ik3B-3sxsA: 41.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 MET A 535 HIS A 621 LEU A 630 ALA A 640	07J A 1 (-3.5A) 07J A 1 (-3.8A) 07J A 1 (-3.8A) None 07J A 1 ( 4.4A) 07J A 1 (-3.2A)	0.57A	3ik3B-3tt0A: 30.6	3ik3B-3tt0A: 34.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 570 VAL A 601 HIS A 677 LEU A 686 ASP A 697	0F4 A 902 (-3.2A) None 0F4 A 902 (-4.1A) 0F4 A 902 (-4.5A) None	0.68A	3ik3B-3v5qA: 28.8	3ik3B-3v5qA: 36.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 866 GLU A 885 HIS A1026 LEU A1035 ASP A1046	4TT A2001 (-3.5A) None None 4TT A2001 (-4.8A) None	0.62A	3ik3B-3vidA: 30.4	3ik3B-3vidA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 866 GLU A 885 ILE A 892 HIS A1026 ASP A1046	4TT A2001 (-3.5A) None None None None	0.64A	3ik3B-3vidA: 30.4	3ik3B-3vidA: 33.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zdu	CYCLIN-DEPENDENT KINASE-LIKE 3 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 31 LEU A 62 VAL A 63 HIS A 123 LEU A 132	38R A 350 (-3.4A) None 38R A 350 ( 4.9A) None 38R A 350 (-4.3A)	0.64A	3ik3B-3zduA: 22.0	3ik3B-3zduA: 28.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 31 GLU A 51 LEU A 63 VAL A 64 HIS A 124 LEU A 133	D15 A 500 (-3.4A) None None None None D15 A 500 (-4.5A)	0.62A	3ik3B-4aguA: 22.5	3ik3B-4aguA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 63 GLU A 81 VAL A 94 ILE A 110 LEU A 164 ALA A 174	XZN A1317 (-3.5A) XZN A1317 (-3.9A) XZN A1317 (-4.4A) XZN A1317 (-3.3A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.73A	3ik3B-4bc6A: 21.5	3ik3B-4bc6A: 29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 63 VAL A 94 ILE A 110 HIS A 155 LEU A 164 ALA A 174	XZN A1317 (-3.5A) XZN A1317 (-4.4A) XZN A1317 (-3.3A) None XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.72A	3ik3B-4bc6A: 21.5	3ik3B-4bc6A: 29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 653 GLU A 672 MET A 676 HIS A 764 LEU A 773 ALA A 783 ASP A 784	DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-4.5A) DI1 A1000 (-3.7A) DI1 A1000 (-4.1A)	0.68A	3ik3B-4ckrA: 32.4	3ik3B-4ckrA: 36.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	MET A 676 HIS A 764 LEU A 773 ALA A 783 ASP A 784 PHE A 785	DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-4.5A) DI1 A1000 (-3.7A) DI1 A1000 (-4.1A) DI1 A1000 (-4.5A)	0.75A	3ik3B-4ckrA: 32.4	3ik3B-4ckrA: 36.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	ALA A 684 GLU A 705 LEU A 720 LEU A 789 ALA A 799	AGS A1985 (-3.5A) None None AGS A1985 (-4.8A) AGS A1985 ( 4.5A)	0.61A	3ik3B-4crsA: 20.6	3ik3B-4crsA: 26.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 853 GLU A 871 HIS A 947 LEU A 956 ALA A 966	19S A1201 (-3.3A) None None 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.48A	3ik3B-4hviA: 24.7	3ik3B-4hviA: 35.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	ALA A 293 LEU A 322 HIS A 384 LEU A 393 ALA A 403	0J9 A 601 (-3.3A) None None 0J9 A 601 (-4.5A) 0J9 A 601 (-3.5A)	0.27A	3ik3B-4k11A: 30.1	3ik3B-4k11A: 34.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	ALA A 293 LEU A 322 VAL A 323 HIS A 384 ALA A 403	0J9 A 601 (-3.3A) None None None 0J9 A 601 (-3.5A)	0.70A	3ik3B-4k11A: 30.1	3ik3B-4k11A: 34.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 506 GLU A 525 MET A 529 ILE A 532 LEU A 624 ALA A 634	ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None None ACP A 801 (-4.4A) None	0.75A	3ik3B-4k33A: 25.7	3ik3B-4k33A: 37.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 506 ILE A 532 HIS A 615 LEU A 624 ALA A 634	ACP A 801 (-3.3A) None None ACP A 801 (-4.4A) None	0.59A	3ik3B-4k33A: 25.7	3ik3B-4k33A: 37.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ALA A 293 LEU A 322 VAL A 323 HIS A 384 LEU A 393 ALA A 403	VGG A 601 (-3.5A) None VGG A 601 ( 4.8A) None VGG A 601 (-4.5A) VGG A 601 ( 4.2A)	0.69A	3ik3B-4lggA: 29.6	3ik3B-4lggA: 46.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o2z	MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE (Leishmania donovani)	PF00069 (Pkinase)	5	GLU A 94 MET A 98 LEU A 106 HIS A 173 ASP A 193	046 A 401 (-3.7A) 046 A 401 (-3.5A) 046 A 401 ( 4.6A) 046 A 401 (-4.1A) 046 A 401 (-4.3A)	0.63A	3ik3B-4o2zA: 21.6	3ik3B-4o2zA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oav	PROTEIN (RNASE L) (Homo sapiens)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A) PF12796 (Ank_2) PF13857 (Ank_5)	5	ALA B 390 LEU B 417 HIS B 483 LEU B 492 ALA B 502	ACP B 801 (-3.2A) None None ACP B 801 (-4.5A) None	0.57A	3ik3B-4oavB: 16.6	3ik3B-4oavB: 17.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oav	PROTEIN (RNASE L) (Homo sapiens)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A) PF12796 (Ank_2) PF13857 (Ank_5)	5	LEU B 417 VAL B 418 HIS B 483 LEU B 492 ALA B 502	None None None ACP B 801 (-4.5A) None	0.70A	3ik3B-4oavB: 16.6	3ik3B-4oavB: 17.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 642 GLU A 661 HIS A 809 LEU A 818 ASP A 829	P30 A1001 (-3.4A) P30 A1001 (-3.6A) P30 A1001 ( 4.3A) P30 A1001 (-4.6A) None	0.42A	3ik3B-4rt7A: 35.0	3ik3B-4rt7A: 31.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tpt	LIM DOMAIN KINASE 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	HIS A 449 LEU A 458 ALA A 468 ASP A 469 PHE A 470	35H A 701 ( 4.4A) None 35H A 701 (-3.5A) 35H A 701 (-4.7A) 35H A 701 (-4.4A)	0.44A	3ik3B-4tptA: 21.8	3ik3B-4tptA: 28.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	ALA A 35 LEU A 64 VAL A 65 HIS A 127 LEU A 136 ALA A 146	ACP A1264 (-2.9A) None None None ACP A1264 ( 4.8A) None	0.52A	3ik3B-4ueuA: 31.9	3ik3B-4ueuA: 63.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 61 VAL A 92 HIS A 153 LEU A 162 ALA A 172 ASP A 173	6UI A 700 (-3.3A) None None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.73A	3ik3B-4usfA: 24.4	3ik3B-4usfA: 29.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 501 GLU A 520 MET A 524 HIS A 610 LEU A 619 ALA A 629	40M A1002 ( 4.1A) 40M A1002 (-3.7A) 40M A1002 (-3.8A) None 40M A1002 (-4.5A) 40M A1002 (-3.0A)	0.54A	3ik3B-4xcuA: 25.7	3ik3B-4xcuA: 39.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	7	ALA B 288 MET B 309 ILE B 312 LEU B 317 HIS B 380 LEU B 389 ALA B 399	1N1 B 601 (-3.5A) 1N1 B 601 (-3.7A) None None None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.59A	3ik3B-4xeyB: 30.1	3ik3B-4xeyB: 92.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 642 GLU A 661 HIS A 809 LEU A 818 ASP A 829	P30 A1001 (-3.5A) P30 A1001 (-3.1A) P30 A1001 (-4.4A) P30 A1001 (-4.3A) None	0.48A	3ik3B-4xufA: 33.2	3ik3B-4xufA: 37.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLU A 661 HIS A 809 LEU A 818 ASP A 829 PHE A 830	P30 A1001 (-3.1A) P30 A1001 (-4.4A) P30 A1001 (-4.3A) None P30 A1001 ( 4.1A)	0.65A	3ik3B-4xufA: 33.2	3ik3B-4xufA: 37.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLU A 661 VAL A 675 HIS A 809 LEU A 818 ASP A 829	P30 A1001 (-3.1A) None P30 A1001 (-4.4A) P30 A1001 (-4.3A) None	0.57A	3ik3B-4xufA: 33.2	3ik3B-4xufA: 37.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 512 GLU A 531 MET A 535 HIS A 621 LEU A 630 ALA A 640	38O A1769 (-3.6A) EDO A1766 (-4.1A) EDO A1766 (-3.5A) None 38O A1769 (-4.6A) EDO A1766 ( 4.4A)	0.52A	3ik3B-5a46A: 25.0	3ik3B-5a46A: 36.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 625 GLU A 644 MET A 648 HIS A 816 LEU A 825 ASP A 836	748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 (-3.8A) 748 A1001 (-4.3A) 748 A1001 (-4.8A)	0.51A	3ik3B-5grnA: 34.6	3ik3B-5grnA: 33.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLU A 644 MET A 648 VAL A 658 HIS A 816 LEU A 825 ASP A 836	748 A1001 (-3.3A) 748 A1001 (-3.4A) 748 A1001 ( 4.8A) 748 A1001 (-3.8A) 748 A1001 (-4.3A) 748 A1001 (-4.8A)	0.70A	3ik3B-5grnA: 34.6	3ik3B-5grnA: 33.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	5	ALA A 41 GLU A 61 VAL A 74 LEU A 143 ALA A 156	ADP A 301 (-3.5A) None None ADP A 301 (-4.7A) ADP A 301 ( 4.8A)	0.59A	3ik3B-5hu3A: 12.5	3ik3B-5hu3A: 26.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	5	ALA A 41 VAL A 74 HIS A 134 LEU A 143 ALA A 156	ADP A 301 (-3.5A) None None ADP A 301 (-4.7A) ADP A 301 ( 4.8A)	0.42A	3ik3B-5hu3A: 12.5	3ik3B-5hu3A: 26.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hx6	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 76 HIS A 136 LEU A 145 ALA A 155 ASP A 156	65U A 301 (-4.7A) 65U A 301 (-3.3A) None 65U A 301 ( 3.9A) 65U A 301 (-4.7A)	0.70A	3ik3B-5hx6A: 21.6	3ik3B-5hx6A: 30.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 43 GLU A 61 MET A 65 HIS A 134 LEU A 143 ALA A 153	6G2 A 901 (-3.2A) None None None 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.70A	3ik3B-5j5tA: 21.5	3ik3B-5j5tA: 24.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 297 GLU A 315 MET A 319 HIS A 387 LEU A 396	IPW A 601 (-3.5A) IPW A 601 (-3.9A) IPW A 601 (-4.1A) None IPW A 601 (-4.5A)	0.69A	3ik3B-5kbrA: 21.5	3ik3B-5kbrA: 24.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	5	ALA A 909 GLU A 927 LEU A 939 VAL A 940 LEU A1016	ATP A1200 (-3.5A) None None None ATP A1200 (-4.6A)	0.71A	3ik3B-5lpyA: 22.2	3ik3B-5lpyA: 29.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	5	ALA A 909 LEU A 939 VAL A 940 HIS A1007 LEU A1016	ATP A1200 (-3.5A) None None None ATP A1200 (-4.6A)	0.57A	3ik3B-5lpyA: 22.2	3ik3B-5lpyA: 29.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	5	ALA A 909 LEU A 939 VAL A 940 HIS A1007 LEU A1016	ADP A1200 (-3.5A) None None None ADP A1200 (-4.7A)	0.58A	3ik3B-5lpzA: 22.2	3ik3B-5lpzA: 29.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5myv	SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 119 GLU A 136 VAL A 157 HIS A 223 ALA A 540	W4A A 716 ( 3.9A) DMS A 717 (-4.0A) DMS A 717 (-4.3A) None DMS A 717 ( 4.5A)	0.67A	3ik3B-5myvA: 19.8	3ik3B-5myvA: 21.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5myv	SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLU A 136 VAL A 157 HIS A 223 LEU A 232 ALA A 540	DMS A 717 (-4.0A) DMS A 717 (-4.3A) None None DMS A 717 ( 4.5A)	0.53A	3ik3B-5myvA: 19.8	3ik3B-5myvA: 21.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7s	FRUCTOSE-1,6-BISPHOS PHATE ALDOLASE (Acinetobacter baumannii)	PF01116 (F_bP_aldolase)	6	ALA A 22 ILE A 192 LEU A 229 VAL A 230 LEU A 10 ALA A 189	None	1.32A	3ik3B-5u7sA: undetectable	3ik3B-5u7sA: 22.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xv7	SERINE-ARGININE (SR) PROTEIN KINASE 1 (Homo sapiens)	no annotation	5	ALA A 107 GLU A 124 VAL A 145 HIS A 211 ALA A 496	EMH A 705 (-3.6A) None EMH A 705 ( 4.9A) None EMH A 705 ( 4.0A)	0.52A	3ik3B-5xv7A: 20.5	3ik3B-5xv7A: 14.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xv7	SERINE-ARGININE (SR) PROTEIN KINASE 1 (Homo sapiens)	no annotation	5	GLU A 124 VAL A 145 HIS A 211 LEU A 220 ALA A 496	None EMH A 705 ( 4.9A) None None EMH A 705 ( 4.0A)	0.62A	3ik3B-5xv7A: 20.5	3ik3B-5xv7A: 14.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	5	ALA A 54 VAL A 83 HIS A 144 LEU A 153 ALA A 163	ANP A 501 ( 3.7A) None None ANP A 501 (-4.6A) None	0.72A	3ik3B-6ao5A: 21.9	3ik3B-6ao5A: 23.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	6	ALA A 754 GLU A 774 VAL A 787 HIS A 857 LEU A 866 ALA A 876	CJM A1102 (-3.1A) None None None CJM A1102 (-4.4A) CJM A1102 (-3.6A)	0.56A	3ik3B-6b3eA: 23.3	3ik3B-6b3eA: 16.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	5	ALA A 192 VAL A 249 HIS A 310 LEU A 319 ALA A 329	BI9 A 501 (-3.3A) None None BI9 A 501 (-4.7A) NH4 A 506 ( 3.7A)	0.53A	3ik3B-6bqlA: 21.6	3ik3B-6bqlA: 16.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	5	ALA A 155 VAL A 212 HIS A 273 LEU A 282 ALA A 292	H1N A 501 (-3.4A) H1N A 501 (-4.9A) None H1N A 501 (-4.8A) H1N A 501 ( 3.9A)	0.50A	3ik3B-6ccfA: 21.9	3ik3B-6ccfA: 13.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	5	ALA A 192 VAL A 249 HIS A 310 LEU A 319 ALA A 329	F6J A 501 (-3.4A) None None F6J A 501 (-4.5A) F6J A 501 ( 4.0A)	0.48A	3ik3B-6cmjA: 22.0	3ik3B-6cmjA: 14.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cnh	SERINE/THREONINE-PRO TEIN KINASE PRP4 HOMOLOG (Homo sapiens)	no annotation	5	ALA A 715 GLU A 732 HIS A 813 LEU A 822 ASP A 834	919 A1101 (-3.5A) 919 A1101 (-3.7A) 919 A1101 (-4.2A) None 919 A1101 (-4.5A)	0.49A	3ik3B-6cnhA: 21.2	3ik3B-6cnhA: 14.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cnh	SERINE/THREONINE-PRO TEIN KINASE PRP4 HOMOLOG (Homo sapiens)	no annotation	5	GLU A 732 HIS A 813 LEU A 822 ASP A 834 PHE A 835	919 A1101 (-3.7A) 919 A1101 (-4.2A) None 919 A1101 (-4.5A) 919 A1101 ( 4.1A)	0.42A	3ik3B-6cnhA: 21.2	3ik3B-6cnhA: 14.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	5	ALA A 211 LEU A 245 VAL A 246 HIS A 309 LEU A 318	CJT A 502 (-3.4A) None None None CJT A 502 (-4.7A)	0.62A	3ik3B-6f3dA: 23.0	3ik3B-6f3dA: 13.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	5	ALA U 42 VAL U 75 HIS U 135 LEU U 144 ALA U 156	DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.67A	3ik3B-6fdyU: 21.6	3ik3B-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	6	ALA A 191 GLU A 208 ILE A 215 VAL A 227 HIS A 288 LEU A 297	3NG A 501 (-3.3A) 3NG A 501 ( 4.9A) None None None None	0.79A	3ik3B-6fylA: 21.5	3ik3B-6fylA: undetectable

[["3IK3_B_0LIB2_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",5,"ALA A  31;VAL A  64;HIS A 124;LEU A 133;ALA A 143","None","0.47A","3ik3B-1h4lA:22.9","3ik3B-1h4lA:24.36"],["3IK3_B_0LIB2_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 220;GLU A 236;MET A 240;LEU A 248;HIS A 312;LEU A 321","None","0.63A","3ik3B-1k9aA:30.5","3ik3B-1k9aA:30.82"],["3IK3_B_0LIB2_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"GLU A 236;MET A 240;LEU A 248;VAL A 249;HIS A 312;LEU A 321","None","0.84A","3ik3B-1k9aA:30.5","3ik3B-1k9aA:30.82"],["3IK3_B_0LIB2_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"ALA A 288;GLU A 305;MET A 309;ILE A 312;LEU A 317;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.57A","3ik3B-1opkA:34.6","3ik3B-1opkA:57.78"],["3IK3_B_0LIB2_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"GLU A 305;MET A 309;LEU A 317;VAL A 318;HIS A 380;LEU A 389","P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);None;P16 A   2 (-4.4A)","0.67A","3ik3B-1opkA:34.6","3ik3B-1opkA:57.78"],["3IK3_B_0LIB2_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"ALA A 621;GLU A 640;HIS A 790;LEU A 799;ASP A 810;PHE A 811","STI A   3 (-3.5A);STI A   3 (-3.6A);STI A   3 (-4.5A);STI A   3 (-4.4A);STI A   3 (-3.9A);STI A   3 (-3.6A)","0.84A","3ik3B-1t46A:29.2","3ik3B-1t46A:35.96"],["3IK3_B_0LIB2_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"ALA A 621;GLU A 640;VAL A 654;HIS A 790;LEU A 799;ASP A 810","STI A   3 (-3.5A);STI A   3 (-3.6A);STI A   3 (-4.3A);STI A   3 (-4.5A);STI A   3 (-4.4A);STI A   3 (-3.9A)","0.48A","3ik3B-1t46A:29.2","3ik3B-1t46A:35.96"],["3IK3_B_0LIB2_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",5,"ALA A 367;GLU A 386;MET A 390;HIS A 459;LEU A 468","STU A 100 (-3.2A);None;None;None;STU A 100 (-4.5A)","0.58A","3ik3B-1u59A:31.3","3ik3B-1u59A:38.05"],["3IK3_B_0LIB2_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"ALA X  37;GLU X  54;MET X  58;LEU X  66;LEU X 137;ALA X 147","STU X 902 (-3.1A);STU X 902 ( 4.4A);None;None;STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.67A","3ik3B-2dq7X:32.1","3ik3B-2dq7X:44.64"],["3IK3_B_0LIB2_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"ALA X  37;MET X  58;LEU X  66;HIS X 128;LEU X 137;ALA X 147","STU X 902 (-3.1A);None;None;None;STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.55A","3ik3B-2dq7X:32.1","3ik3B-2dq7X:44.64"],["3IK3_B_0LIB2_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"GLU X  54;MET X  58;LEU X  66;VAL X  67;LEU X 137;ALA X 147","STU X 902 ( 4.4A);None;None;None;STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.81A","3ik3B-2dq7X:32.1","3ik3B-2dq7X:44.64"],["3IK3_B_0LIB2_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"MET X  58;LEU X  66;VAL X  67;HIS X 128;LEU X 137;ALA X 147","None;None;None;None;STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.74A","3ik3B-2dq7X:32.1","3ik3B-2dq7X:44.64"],["3IK3_B_0LIB2_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",7,"ALA A 184;GLU A 201;ILE A 208;VAL A 220;HIS A 281;LEU A 290;ALA A 319","None","0.69A","3ik3B-2eu9A:21.3","3ik3B-2eu9A:23.86"],["3IK3_B_0LIB2_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;LEU A 322;VAL A 323;HIS A 384;LEU A 393;ALA A 403","H8H A 534 (-3.2A);None;None;None;H8H A 534 (-4.5A);H8H A 534 ( 4.0A)","0.83A","3ik3B-2h8hA:30.2","3ik3B-2h8hA:27.49"],["3IK3_B_0LIB2_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 293;LEU A 322;VAL A 323;HIS A 384;LEU A 393;ALA A 403","QUE A   1 (-3.5A);None;None;None;QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.64A","3ik3B-2hckA:29.8","3ik3B-2hckA:31.34"],["3IK3_B_0LIB2_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"ALA A 271;MET A 292;LEU A 300;VAL A 301;HIS A 362;LEU A 371;ALA A 381","1BM A 499 (-3.6A);1BM A 499 ( 3.8A);None;None;None;1BM A 499 (-4.4A);1BM A 499 ( 3.7A)","0.80A","3ik3B-2hk5A:26.9","3ik3B-2hk5A:46.45"],["3IK3_B_0LIB2_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"ALA A 269;GLU A 286;MET A 290;ILE A 293;LEU A 298;LEU A 370;ALA A 380","GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.39A","3ik3B-2hz0A:33.9","3ik3B-2hz0A:98.89"],["3IK3_B_0LIB2_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"ALA A 269;MET A 290;ILE A 293;LEU A 298;HIS A 361;LEU A 370;ALA A 380","GIN A 600 (-3.1A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-4.3A);GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.62A","3ik3B-2hz0A:33.9","3ik3B-2hz0A:98.89"],["3IK3_B_0LIB2_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"GLU A 286;MET A 290;ILE A 293;LEU A 298;VAL A 299;LEU A 370;ALA A 380;ASP A 381","GIN A 600 (-3.6A);GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-4.6A);GIN A 600 (-4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.81A","3ik3B-2hz0A:33.9","3ik3B-2hz0A:98.89"],["3IK3_B_0LIB2_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"MET A 290;ILE A 293;LEU A 298;VAL A 299;HIS A 361;LEU A 370;ALA A 380;ASP A 381","GIN A 600 (-3.2A);GIN A 600 (-4.5A);GIN A 600 (-4.2A);GIN A 600 (-4.6A);GIN A 600 (-4.3A);GIN A 600 (-4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.75A","3ik3B-2hz0A:33.9","3ik3B-2hz0A:98.89"],["3IK3_B_0LIB2_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",5,"ALA A 452;GLU A 471;MET A 475;HIS A 544;LEU A 553","4ST A1687 (-3.3A);4ST A1687 ( 4.6A);None;None;4ST A1687 (-4.4A)","0.58A","3ik3B-2j0jA:32.5","3ik3B-2j0jA:19.97"],["3IK3_B_0LIB2_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",5,"ALA A  31;GLU A  51;VAL A  64;LEU A 134;ALA A 144","None","0.55A","3ik3B-2jgzA:23.0","3ik3B-2jgzA:27.81"],["3IK3_B_0LIB2_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",5,"ALA A  31;VAL A  64;HIS A 125;LEU A 134;ALA A 144","None","0.39A","3ik3B-2jgzA:23.0","3ik3B-2jgzA:27.81"],["3IK3_B_0LIB2_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",10,"ALA A 271;GLU A 288;MET A 292;LEU A 300;VAL A 301;HIS A 362;LEU A 371;ALA A 381;ASP A 382;PHE A 383","1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.9A);None;None;1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.3A);1N8 A 501 ( 4.3A)","0.62A","3ik3B-2og8A:32.0","3ik3B-2og8A:44.95"],["3IK3_B_0LIB2_1","2p4i","Homo sapiens","ANGIOPOIETIN-1 RECEPTOR","PF07714(Pkinase_Tyr)",7,"ALA A 853;ILE A 902;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-4.1A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.54A","3ik3B-2p4iA:23.3","3ik3B-2p4iA:38.06"],["3IK3_B_0LIB2_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"ALA A 515;GLU A 534;MET A 538;ILE A 541;HIS A 624;LEU A 633;ALA A 643","None","0.70A","3ik3B-2psqA:31.8","3ik3B-2psqA:33.68"],["3IK3_B_0LIB2_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",5,"ALA A 215;LEU A 244;HIS A 319;LEU A 328;ALA A 338","ADE A 488 (-3.2A);None;None;ADE A 488 (-4.4A);None","0.50A","3ik3B-2qluA:24.4","3ik3B-2qluA:23.36"],["3IK3_B_0LIB2_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",5,"ALA A 749;LEU A 780;VAL A 781;HIS A 841;LEU A 850","GW7 A   1 (-3.3A);None;GW7 A   1 ( 4.7A);None;GW7 A   1 (-4.2A)","0.71A","3ik3B-2r4bA:29.0","3ik3B-2r4bA:35.94"],["3IK3_B_0LIB2_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",5,"ALA A 273;LEU A 302;HIS A 365;LEU A 374;ALA A 384","None","0.44A","3ik3B-2zv7A:25.6","3ik3B-2zv7A:45.14"],["3IK3_B_0LIB2_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",5,"ALA A 515;MET A 538;HIS A 624;LEU A 633;ALA A 643","M33 A1996 (-3.3A);None;None;M33 A1996 (-4.5A);None","0.55A","3ik3B-3b2tA:25.6","3ik3B-3b2tA:39.94"],["3IK3_B_0LIB2_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"ALA A 512;GLU A 531;HIS A 621;LEU A 630;ALA A 640","C4F A   1 (-3.3A);None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.49A","3ik3B-3c4fA:25.2","3ik3B-3c4fA:40.26"],["3IK3_B_0LIB2_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"ALA A 512;MET A 535;HIS A 621;LEU A 630;ALA A 640","C4F A   1 (-3.3A);C4F A   1 ( 3.7A);None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.49A","3ik3B-3c4fA:25.2","3ik3B-3c4fA:40.26"],["3IK3_B_0LIB2_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ALA A 220;GLU A 236;MET A 240;LEU A 248;HIS A 312;LEU A 321","None","0.63A","3ik3B-3d7uA:31.2","3ik3B-3d7uA:44.33"],["3IK3_B_0LIB2_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"GLU A 236;MET A 240;LEU A 248;VAL A 249;HIS A 312;LEU A 321","None","0.84A","3ik3B-3d7uA:31.2","3ik3B-3d7uA:44.33"],["3IK3_B_0LIB2_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ALA A 663;GLU A 682;MET A 686;VAL A 695;HIS A 756;ASP A 776;PHE A 777","IHZ A1001 (-3.3A);IHZ A1001 (-3.8A);IHZ A1001 (-3.5A);IHZ A1001 ( 4.9A);IHZ A1001 ( 4.9A);IHZ A1001 (-4.8A);IHZ A1001 (-4.7A)","0.76A","3ik3B-3dkoA:30.9","3ik3B-3dkoA:36.98"],["3IK3_B_0LIB2_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ALA A 663;VAL A 695;ILE A 711;HIS A 756;LEU A 765;ASP A 776;PHE A 777","IHZ A1001 (-3.3A);IHZ A1001 ( 4.9A);IHZ A1001 (-3.8A);IHZ A1001 ( 4.9A);IHZ A1001 (-4.6A);IHZ A1001 (-4.8A);IHZ A1001 (-4.7A)","0.86A","3ik3B-3dkoA:30.9","3ik3B-3dkoA:36.98"],["3IK3_B_0LIB2_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 859;GLU A 878;HIS A1020;LEU A1029;ASP A1040;PHE A1041","8ST A2001 ( 3.8A);8ST A2001 (-3.7A);8ST A2001 ( 4.8A);None;None;8ST A2001 ( 3.7A)","0.93A","3ik3B-3hngA:33.0","3ik3B-3hngA:33.77"],["3IK3_B_0LIB2_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",5,"ALA A 665;GLU A 684;MET A 688;HIS A 758;LEU A 767","None","0.54A","3ik3B-3kulA:25.8","3ik3B-3kulA:34.78"],["3IK3_B_0LIB2_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",5,"ALA A  46;GLU A  66;VAL A  79;LEU A 156;ALA A 166","None","0.56A","3ik3B-3mi9A:22.7","3ik3B-3mi9A:26.16"],["3IK3_B_0LIB2_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",5,"ALA A  46;VAL A  79;HIS A 147;LEU A 156;ALA A 166","None","0.50A","3ik3B-3mi9A:22.7","3ik3B-3mi9A:26.16"],["3IK3_B_0LIB2_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",5,"ALA A  49;VAL A  82;HIS A 142;LEU A 151;ALA A 161","ADP A 314 (-3.5A);None;None;ADP A 314 (-4.6A);None","0.57A","3ik3B-3nizA:22.6","3ik3B-3nizA:27.10"],["3IK3_B_0LIB2_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",5,"ALA A 109;GLU A 130;MET A 134;HIS A 203;LEU A 212","JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);None;None;None","0.57A","3ik3B-3nuuA:22.8","3ik3B-3nuuA:26.07"],["3IK3_B_0LIB2_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",5,"ALA A 576;GLU A 596;MET A 600;HIS A 674;LEU A 683","STU A   1 (-3.3A);None;None;None;STU A   1 (-4.3A)","0.53A","3ik3B-3ppzA:28.4","3ik3B-3ppzA:32.81"],["3IK3_B_0LIB2_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",5,"ALA A 576;MET A 600;VAL A 609;HIS A 674;LEU A 683","STU A   1 (-3.3A);None;None;None;STU A   1 (-4.3A)","0.71A","3ik3B-3ppzA:28.4","3ik3B-3ppzA:32.81"],["3IK3_B_0LIB2_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"ALA A 443;MET A 464;LEU A 472;VAL A 473;HIS A 534;LEU A 543","PP2 A   1 (-3.2A);PP2 A   1 ( 4.3A);None;None;None;PP2 A   1 (-4.6A)","0.68A","3ik3B-3sxsA:31.3","3ik3B-3sxsA:41.81"],["3IK3_B_0LIB2_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;MET A 535;HIS A 621;LEU A 630;ALA A 640","07J A   1 (-3.5A);07J A   1 (-3.8A);07J A   1 (-3.8A);None;07J A   1 ( 4.4A);07J A   1 (-3.2A)","0.57A","3ik3B-3tt0A:30.6","3ik3B-3tt0A:34.11"],["3IK3_B_0LIB2_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"ALA A 570;VAL A 601;HIS A 677;LEU A 686;ASP A 697","0F4 A 902 (-3.2A);None;0F4 A 902 (-4.1A);0F4 A 902 (-4.5A);None","0.68A","3ik3B-3v5qA:28.8","3ik3B-3v5qA:36.33"],["3IK3_B_0LIB2_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",5,"ALA A 866;GLU A 885;HIS A1026;LEU A1035;ASP A1046","4TT A2001 (-3.5A);None;None;4TT A2001 (-4.8A);None","0.62A","3ik3B-3vidA:30.4","3ik3B-3vidA:33.33"],["3IK3_B_0LIB2_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",5,"ALA A 866;GLU A 885;ILE A 892;HIS A1026;ASP A1046","4TT A2001 (-3.5A);None;None;None;None","0.64A","3ik3B-3vidA:30.4","3ik3B-3vidA:33.33"],["3IK3_B_0LIB2_1","3zdu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 3","PF00069(Pkinase)",5,"ALA A  31;LEU A  62;VAL A  63;HIS A 123;LEU A 132","38R A 350 (-3.4A);None;38R A 350 ( 4.9A);None;38R A 350 (-4.3A)","0.64A","3ik3B-3zduA:22.0","3ik3B-3zduA:28.65"],["3IK3_B_0LIB2_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",6,"ALA A  31;GLU A  51;LEU A  63;VAL A  64;HIS A 124;LEU A 133","D15 A 500 (-3.4A);None;None;None;None;D15 A 500 (-4.5A)","0.62A","3ik3B-4aguA:22.5","3ik3B-4aguA:28.00"],["3IK3_B_0LIB2_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"ALA A  63;GLU A  81;VAL A  94;ILE A 110;LEU A 164;ALA A 174","XZN A1317 (-3.5A);XZN A1317 (-3.9A);XZN A1317 (-4.4A);XZN A1317 (-3.3A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.73A","3ik3B-4bc6A:21.5","3ik3B-4bc6A:29.71"],["3IK3_B_0LIB2_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"ALA A  63;VAL A  94;ILE A 110;HIS A 155;LEU A 164;ALA A 174","XZN A1317 (-3.5A);XZN A1317 (-4.4A);XZN A1317 (-3.3A);None;XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.72A","3ik3B-4bc6A:21.5","3ik3B-4bc6A:29.71"],["3IK3_B_0LIB2_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"ALA A 653;GLU A 672;MET A 676;HIS A 764;LEU A 773;ALA A 783;ASP A 784","DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-4.5A);DI1 A1000 (-3.7A);DI1 A1000 (-4.1A)","0.68A","3ik3B-4ckrA:32.4","3ik3B-4ckrA:36.67"],["3IK3_B_0LIB2_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"MET A 676;HIS A 764;LEU A 773;ALA A 783;ASP A 784;PHE A 785","DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-4.5A);DI1 A1000 (-3.7A);DI1 A1000 (-4.1A);DI1 A1000 (-4.5A)","0.75A","3ik3B-4ckrA:32.4","3ik3B-4ckrA:36.67"],["3IK3_B_0LIB2_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",5,"ALA A 684;GLU A 705;LEU A 720;LEU A 789;ALA A 799","AGS A1985 (-3.5A);None;None;AGS A1985 (-4.8A);AGS A1985 ( 4.5A)","0.61A","3ik3B-4crsA:20.6","3ik3B-4crsA:26.05"],["3IK3_B_0LIB2_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",5,"ALA A 853;GLU A 871;HIS A 947;LEU A 956;ALA A 966","19S A1201 (-3.3A);None;None;19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.48A","3ik3B-4hviA:24.7","3ik3B-4hviA:35.02"],["3IK3_B_0LIB2_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"ALA A 293;LEU A 322;HIS A 384;LEU A 393;ALA A 403","0J9 A 601 (-3.3A);None;None;0J9 A 601 (-4.5A);0J9 A 601 (-3.5A)","0.27A","3ik3B-4k11A:30.1","3ik3B-4k11A:34.10"],["3IK3_B_0LIB2_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"ALA A 293;LEU A 322;VAL A 323;HIS A 384;ALA A 403","0J9 A 601 (-3.3A);None;None;None;0J9 A 601 (-3.5A)","0.70A","3ik3B-4k11A:30.1","3ik3B-4k11A:34.10"],["3IK3_B_0LIB2_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",6,"ALA A 506;GLU A 525;MET A 529;ILE A 532;LEU A 624;ALA A 634","ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;None;ACP A 801 (-4.4A);None","0.75A","3ik3B-4k33A:25.7","3ik3B-4k33A:37.31"],["3IK3_B_0LIB2_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",5,"ALA A 506;ILE A 532;HIS A 615;LEU A 624;ALA A 634","ACP A 801 (-3.3A);None;None;ACP A 801 (-4.4A);None","0.59A","3ik3B-4k33A:25.7","3ik3B-4k33A:37.31"],["3IK3_B_0LIB2_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"ALA A 293;LEU A 322;VAL A 323;HIS A 384;LEU A 393;ALA A 403","VGG A 601 (-3.5A);None;VGG A 601 ( 4.8A);None;VGG A 601 (-4.5A);VGG A 601 ( 4.2A)","0.69A","3ik3B-4lggA:29.6","3ik3B-4lggA:46.53"],["3IK3_B_0LIB2_1","4o2z","Leishmania donovani","MITOGEN-ACTIVATED PROTEIN KINASE 3, PUTATIVE","PF00069(Pkinase)",5,"GLU A  94;MET A  98;LEU A 106;HIS A 173;ASP A 193","046 A 401 (-3.7A);046 A 401 (-3.5A);046 A 401 ( 4.6A);046 A 401 (-4.1A);046 A 401 (-4.3A)","0.63A","3ik3B-4o2zA:21.6","3ik3B-4o2zA:24.93"],["3IK3_B_0LIB2_1","4oav","Homo sapiens","PROTEIN (RNASE L)","PF00069(Pkinase);PF06479(Ribonuc_2-5A);PF12796(Ank_2);PF13857(Ank_5)",5,"ALA B 390;LEU B 417;HIS B 483;LEU B 492;ALA B 502","ACP B 801 (-3.2A);None;None;ACP B 801 (-4.5A);None","0.57A","3ik3B-4oavB:16.6","3ik3B-4oavB:17.11"],["3IK3_B_0LIB2_1","4oav","Homo sapiens","PROTEIN (RNASE L)","PF00069(Pkinase);PF06479(Ribonuc_2-5A);PF12796(Ank_2);PF13857(Ank_5)",5,"LEU B 417;VAL B 418;HIS B 483;LEU B 492;ALA B 502","None;None;None;ACP B 801 (-4.5A);None","0.70A","3ik3B-4oavB:16.6","3ik3B-4oavB:17.11"],["3IK3_B_0LIB2_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",5,"ALA A 642;GLU A 661;HIS A 809;LEU A 818;ASP A 829","P30 A1001 (-3.4A);P30 A1001 (-3.6A);P30 A1001 ( 4.3A);P30 A1001 (-4.6A);None","0.42A","3ik3B-4rt7A:35.0","3ik3B-4rt7A:31.25"],["3IK3_B_0LIB2_1","4tpt","Homo sapiens","LIM DOMAIN KINASE 2","PF07714(Pkinase_Tyr)",5,"HIS A 449;LEU A 458;ALA A 468;ASP A 469;PHE A 470","35H A 701 ( 4.4A);None;35H A 701 (-3.5A);35H A 701 (-4.7A);35H A 701 (-4.4A)","0.44A","3ik3B-4tptA:21.8","3ik3B-4tptA:28.75"],["3IK3_B_0LIB2_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"ALA A  35;LEU A  64;VAL A  65;HIS A 127;LEU A 136;ALA A 146","ACP A1264 (-2.9A);None;None;None;ACP A1264 ( 4.8A);None","0.52A","3ik3B-4ueuA:31.9","3ik3B-4ueuA:63.54"],["3IK3_B_0LIB2_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",6,"ALA A  61;VAL A  92;HIS A 153;LEU A 162;ALA A 172;ASP A 173","6UI A 700 (-3.3A);None;None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.73A","3ik3B-4usfA:24.4","3ik3B-4usfA:29.05"],["3IK3_B_0LIB2_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"ALA A 501;GLU A 520;MET A 524;HIS A 610;LEU A 619;ALA A 629","40M A1002 ( 4.1A);40M A1002 (-3.7A);40M A1002 (-3.8A);None;40M A1002 (-4.5A);40M A1002 (-3.0A)","0.54A","3ik3B-4xcuA:25.7","3ik3B-4xcuA:39.29"],["3IK3_B_0LIB2_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",7,"ALA B 288;MET B 309;ILE B 312;LEU B 317;HIS B 380;LEU B 389;ALA B 399","1N1 B 601 (-3.5A);1N1 B 601 (-3.7A);None;None;None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.59A","3ik3B-4xeyB:30.1","3ik3B-4xeyB:92.21"],["3IK3_B_0LIB2_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",5,"ALA A 642;GLU A 661;HIS A 809;LEU A 818;ASP A 829","P30 A1001 (-3.5A);P30 A1001 (-3.1A);P30 A1001 (-4.4A);P30 A1001 (-4.3A);None","0.48A","3ik3B-4xufA:33.2","3ik3B-4xufA:37.35"],["3IK3_B_0LIB2_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",5,"GLU A 661;HIS A 809;LEU A 818;ASP A 829;PHE A 830","P30 A1001 (-3.1A);P30 A1001 (-4.4A);P30 A1001 (-4.3A);None;P30 A1001 ( 4.1A)","0.65A","3ik3B-4xufA:33.2","3ik3B-4xufA:37.35"],["3IK3_B_0LIB2_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",5,"GLU A 661;VAL A 675;HIS A 809;LEU A 818;ASP A 829","P30 A1001 (-3.1A);None;P30 A1001 (-4.4A);P30 A1001 (-4.3A);None","0.57A","3ik3B-4xufA:33.2","3ik3B-4xufA:37.35"],["3IK3_B_0LIB2_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"ALA A 512;GLU A 531;MET A 535;HIS A 621;LEU A 630;ALA A 640","38O A1769 (-3.6A);EDO A1766 (-4.1A);EDO A1766 (-3.5A);None;38O A1769 (-4.6A);EDO A1766 ( 4.4A)","0.52A","3ik3B-5a46A:25.0","3ik3B-5a46A:36.46"],["3IK3_B_0LIB2_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"ALA A 625;GLU A 644;MET A 648;HIS A 816;LEU A 825;ASP A 836","748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 (-3.8A);748 A1001 (-4.3A);748 A1001 (-4.8A)","0.51A","3ik3B-5grnA:34.6","3ik3B-5grnA:33.80"],["3IK3_B_0LIB2_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"GLU A 644;MET A 648;VAL A 658;HIS A 816;LEU A 825;ASP A 836","748 A1001 (-3.3A);748 A1001 (-3.4A);748 A1001 ( 4.8A);748 A1001 (-3.8A);748 A1001 (-4.3A);748 A1001 (-4.8A)","0.70A","3ik3B-5grnA:34.6","3ik3B-5grnA:33.80"],["3IK3_B_0LIB2_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",5,"ALA A  41;GLU A  61;VAL A  74;LEU A 143;ALA A 156","ADP A 301 (-3.5A);None;None;ADP A 301 (-4.7A);ADP A 301 ( 4.8A)","0.59A","3ik3B-5hu3A:12.5","3ik3B-5hu3A:26.42"],["3IK3_B_0LIB2_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",5,"ALA A  41;VAL A  74;HIS A 134;LEU A 143;ALA A 156","ADP A 301 (-3.5A);None;None;ADP A 301 (-4.7A);ADP A 301 ( 4.8A)","0.42A","3ik3B-5hu3A:12.5","3ik3B-5hu3A:26.42"],["3IK3_B_0LIB2_1","5hx6","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF07714(Pkinase_Tyr)",5,"VAL A  76;HIS A 136;LEU A 145;ALA A 155;ASP A 156","65U A 301 (-4.7A);65U A 301 (-3.3A);None;65U A 301 ( 3.9A);65U A 301 (-4.7A)","0.70A","3ik3B-5hx6A:21.6","3ik3B-5hx6A:30.35"],["3IK3_B_0LIB2_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"ALA A  43;GLU A  61;MET A  65;HIS A 134;LEU A 143;ALA A 153","6G2 A 901 (-3.2A);None;None;None;6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.70A","3ik3B-5j5tA:21.5","3ik3B-5j5tA:24.69"],["3IK3_B_0LIB2_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",5,"ALA A 297;GLU A 315;MET A 319;HIS A 387;LEU A 396","IPW A 601 (-3.5A);IPW A 601 (-3.9A);IPW A 601 (-4.1A);None;IPW A 601 (-4.5A)","0.69A","3ik3B-5kbrA:21.5","3ik3B-5kbrA:24.58"],["3IK3_B_0LIB2_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",5,"ALA A 909;GLU A 927;LEU A 939;VAL A 940;LEU A1016","ATP A1200 (-3.5A);None;None;None;ATP A1200 (-4.6A)","0.71A","3ik3B-5lpyA:22.2","3ik3B-5lpyA:29.25"],["3IK3_B_0LIB2_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",5,"ALA A 909;LEU A 939;VAL A 940;HIS A1007;LEU A1016","ATP A1200 (-3.5A);None;None;None;ATP A1200 (-4.6A)","0.57A","3ik3B-5lpyA:22.2","3ik3B-5lpyA:29.25"],["3IK3_B_0LIB2_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",5,"ALA A 909;LEU A 939;VAL A 940;HIS A1007;LEU A1016","ADP A1200 (-3.5A);None;None;None;ADP A1200 (-4.7A)","0.58A","3ik3B-5lpzA:22.2","3ik3B-5lpzA:29.62"],["3IK3_B_0LIB2_1","5myv","Homo sapiens","SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2","PF00069(Pkinase)",5,"ALA A 119;GLU A 136;VAL A 157;HIS A 223;ALA A 540","W4A A 716 ( 3.9A);DMS A 717 (-4.0A);DMS A 717 (-4.3A);None;DMS A 717 ( 4.5A)","0.67A","3ik3B-5myvA:19.8","3ik3B-5myvA:21.48"],["3IK3_B_0LIB2_1","5myv","Homo sapiens","SRSF PROTEIN KINASE 2,SRSF PROTEIN KINASE 2","PF00069(Pkinase)",5,"GLU A 136;VAL A 157;HIS A 223;LEU A 232;ALA A 540","DMS A 717 (-4.0A);DMS A 717 (-4.3A);None;None;DMS A 717 ( 4.5A)","0.53A","3ik3B-5myvA:19.8","3ik3B-5myvA:21.48"],["3IK3_B_0LIB2_1","5u7s","Acinetobacter baumannii","FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE","PF01116(F_bP_aldolase)",6,"ALA A  22;ILE A 192;LEU A 229;VAL A 230;LEU A  10;ALA A 189","None","1.32A","3ik3B-5u7sA:undetectable","3ik3B-5u7sA:22.19"],["3IK3_B_0LIB2_1","5xv7","Homo sapiens","SERINE-ARGININE (SR) PROTEIN KINASE 1","no annotation",5,"ALA A 107;GLU A 124;VAL A 145;HIS A 211;ALA A 496","EMH A 705 (-3.6A);None;EMH A 705 ( 4.9A);None;EMH A 705 ( 4.0A)","0.52A","3ik3B-5xv7A:20.5","3ik3B-5xv7A:14.63"],["3IK3_B_0LIB2_1","5xv7","Homo sapiens","SERINE-ARGININE (SR) PROTEIN KINASE 1","no annotation",5,"GLU A 124;VAL A 145;HIS A 211;LEU A 220;ALA A 496","None;EMH A 705 ( 4.9A);None;None;EMH A 705 ( 4.0A)","0.62A","3ik3B-5xv7A:20.5","3ik3B-5xv7A:14.63"],["3IK3_B_0LIB2_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",5,"ALA A  54;VAL A  83;HIS A 144;LEU A 153;ALA A 163","ANP A 501 ( 3.7A);None;None;ANP A 501 (-4.6A);None","0.72A","3ik3B-6ao5A:21.9","3ik3B-6ao5A:23.60"],["3IK3_B_0LIB2_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",6,"ALA A 754;GLU A 774;VAL A 787;HIS A 857;LEU A 866;ALA A 876","CJM A1102 (-3.1A);None;None;None;CJM A1102 (-4.4A);CJM A1102 (-3.6A)","0.56A","3ik3B-6b3eA:23.3","3ik3B-6b3eA:16.30"],["3IK3_B_0LIB2_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",5,"ALA A 192;VAL A 249;HIS A 310;LEU A 319;ALA A 329","BI9 A 501 (-3.3A);None;None;BI9 A 501 (-4.7A);NH4 A 506 ( 3.7A)","0.53A","3ik3B-6bqlA:21.6","3ik3B-6bqlA:16.29"],["3IK3_B_0LIB2_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",5,"ALA A 155;VAL A 212;HIS A 273;LEU A 282;ALA A 292","H1N A 501 (-3.4A);H1N A 501 (-4.9A);None;H1N A 501 (-4.8A);H1N A 501 ( 3.9A)","0.50A","3ik3B-6ccfA:21.9","3ik3B-6ccfA:13.91"],["3IK3_B_0LIB2_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",5,"ALA A 192;VAL A 249;HIS A 310;LEU A 319;ALA A 329","F6J A 501 (-3.4A);None;None;F6J A 501 (-4.5A);F6J A 501 ( 4.0A)","0.48A","3ik3B-6cmjA:22.0","3ik3B-6cmjA:14.18"],["3IK3_B_0LIB2_1","6cnh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PRP4 HOMOLOG","no annotation",5,"ALA A 715;GLU A 732;HIS A 813;LEU A 822;ASP A 834","919 A1101 (-3.5A);919 A1101 (-3.7A);919 A1101 (-4.2A);None;919 A1101 (-4.5A)","0.49A","3ik3B-6cnhA:21.2","3ik3B-6cnhA:14.78"],["3IK3_B_0LIB2_1","6cnh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PRP4 HOMOLOG","no annotation",5,"GLU A 732;HIS A 813;LEU A 822;ASP A 834;PHE A 835","919 A1101 (-3.7A);919 A1101 (-4.2A);None;919 A1101 (-4.5A);919 A1101 ( 4.1A)","0.42A","3ik3B-6cnhA:21.2","3ik3B-6cnhA:14.78"],["3IK3_B_0LIB2_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",5,"ALA A 211;LEU A 245;VAL A 246;HIS A 309;LEU A 318","CJT A 502 (-3.4A);None;None;None;CJT A 502 (-4.7A)","0.62A","3ik3B-6f3dA:23.0","3ik3B-6f3dA:13.45"],["3IK3_B_0LIB2_1","6fdy","-","-","no annotation",5,"ALA U  42;VAL U  75;HIS U 135;LEU U 144;ALA U 156","DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.67A","3ik3B-6fdyU:21.6","3ik3B-6fdyU:undetectable"],["3IK3_B_0LIB2_1","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",6,"ALA A 191;GLU A 208;ILE A 215;VAL A 227;HIS A 288;LEU A 297","3NG A 501 (-3.3A);3NG A 501 ( 4.9A);None;None;None;None","0.79A","3ik3B-6fylA:21.5","3ik3B-6fylA:undetectable"]]